|
1
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Knox JJ, Cleary SP and Dawson LA:
Localized and systemic approaches to treating hepatocellular
carcinoma. J Clin Oncol. 33:1835–1844. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Zijl F, Zulehner G, Petz M, Schneller
D, Kornauth C, Hau M, Machat G, Grubinger M, Huber H and Mikulits
W: Epithelial-mesenchymal transition in hepatocellular carcinoma.
Future Oncol. 5:1169–1179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vaira V, Lee CW, Goel HL, Bosari S,
Languino LR and Altieri DC: Regulation of survivin expression by
IGF-1/mTOR signaling. Oncogene. 26:2678–2684. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Haisa M: The type 1 insulin-like growth
factor receptor signalling system and targeted tyrosine kinase
inhibition in cancer. J Int Med Res. 41:253–264. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liao G, Wang M, Ou Y and Zhao Y:
IGF-1-induced epithelial-mesenchymal transition in MCF-7 cells is
mediated by MUC1. Cell Signal. 26:2131–2137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lei T and Ling X: IGF-1 promotes the
growth and metastasis of hepatocellular carcinoma via the
inhibition of proteasome-mediated cathepsin B degradation. World J
Gastroenterol. 21:10137–10149. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Su C: Survivin in survival of
hepatocellular carcinoma. Cancer Lett. 379:184–190. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang P, Wang G, Huo H, Li Q, Zhao Y and
Liu Y: SDF-1/CXCR4 signaling up-regulates survivin to regulate
human sacral chondrosarcoma cell cycle and epithelial-mesenchymal
transition via ERK and PI3K/AKT pathway. Med Oncol. 32:3772015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tai CJ, Chin-Sheng H, Kuo LJ, Wei PL, Lu
HH, Chen HA, Liu TZ, Liu JJ, Liu DZ, Ho YS, et al:
Survivin-mediated cancer cell migration through GRP78 and
epithelial-mesenchymal transition (EMT) marker expression in
Mahlavu cells. Ann Surg Oncol. 19:336–343. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Khan S, Aspe JR, Asumen MG, Almaguel F,
Odumosu O, Acevedo-Martinez S, De Leon M, Langridge WH and Wall NR:
Extracellular, cell-permeable survivin inhibits apoptosis while
promoting proliferative and metastatic potential. Br J Cancer.
100:1073–1086. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hollier BG, Evans K and Mani SA:
Identication of optimal topography of the barotropic ocean model in
the North Atlantic by variational data assimilation. Mol Cell
Endocrinol. 138:41–50. 2009.
|
|
15
|
Onoue T, Uchida D, Begum NM, Tomizuka Y,
Yoshida H and Sato M: Epithelial-mesenchymal transitions induced by
the stromal cell-derived factor-1/CXCR4 system in oral squamous
cell carcinoma cells. Int J Oncol. 29:1133–1138. 2006.PubMed/NCBI
|
|
16
|
Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW,
Yun JP, Zhang MF and Wan DS: Elevated expressions of MMP7, TROP2,
and survivin are associated with survival, disease recurrence, and
liver metastasis of colon cancer. Int J Colorectal Dis. 24:875–884.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
DeNardo BD, Holloway MP, Ji Q, Nguyen KT,
Cheng Y, Valentine MB, Salomon A and Altura RA: Quantitative
phosphoproteomic analysis identifies activation of the RET and
IGF-1R/IR signaling pathways in neuroblastoma. PLoS One. 8:e82513.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen J, Alberts I and Li X: Dysregulation
of the IGF-I/PI3K/AKT/mTOR signaling pathway in autism spectrum
disorders. Int J Dev Neurosci. 35:35–41. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Onder TT, Gupta PB, Mani SA, Yang J,
Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis
via multiple downstream transcriptional pathways. Cancer Res.
68:3645–3654. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Canel M, Serrels A, Frame MC and Brunton
VG: E-cadherin-integrin crosstalk in cancer invasion and
metastasis. J Cell Sci. 126:393–401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cell Mol
Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ivaska J, Pallari HM, Nevo J and Eriksson
JE: Novel functions of vimentin in cell adhesion, migration, and
signaling. Exp Cell Res. 313:2050–2062. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kudo-Saito C, Shirako H, Takeuchi T and
Kawakami Y: Cancer metastasis is accelerated through
immunosuppression during Snail-induced EMT of cancer cells. Cancer
Cell. 15:195–206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou BP, Deng J, Xia W, Xu J, Li YM,
Gunduz M and Hung MC: Dual regulation of Snail by
GSK-3beta-mediated phosphorylation in control of
epithelial-mesenchymal transition. Nat Cell Biol. 6:931–940. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cosgrove BD, Mui KL, Driscoll TP, Caliari
SR, Mehta KD, Assoian RK, Burdick JA and Mauck RL: N-cadherin
adhesive interactions modulate matrix mechanosensing and fate
commitment of mesenchymal stem cells. Nat Mater. 15:1297–1306.
2016. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Amsellem V, Dryden NH, Martinelli R,
Gavins F, Almagro LO, Birdsey GM, Haskard DO, Mason JC, Turowski P
and Randi AM: ICAM-2 regulates vascular permeability and N-cadherin
localization through ezrin-radixin-moesin (ERM) proteins and Rac-1
signalling. Cell Commun Signal. 12:122014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen YS, Huang WL, Chang SH, Chang KW, Kao
SY, Lo JF and Su PF: Enhanced filopodium formation and stem-like
phenotypes in a novel metastatic head and neck cancer cell model.
Oncol Rep. 30:2829–2837. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sigurdsson V, Hilmarsdottir B,
Sigmundsdottir H, Fridriksdottir AJ, Ringnér M, Villadsen R, Borg
A, Agnarsson BA, Petersen OW, Magnusson MK, et al: Endothelial
induced EMT in breast epithelial cells with stem cell properties.
PLoS One. 6:e238332011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ma J, Sawai H, Matsuo Y, Ochi N, Yasuda A,
Takahashi H, Wakasugi T, Funahashi H, Sato M and Takeyama H: IGF-1
mediates PTEN suppression and enhances cell invasion and
proliferation via activation of the IGF-1/PI3K/Akt signaling
pathway in pancreatic cancer cells. J Surg Res. 160:90–101. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Walsh LA and Damjanovski S: IGF-1
increases invasive potential of MCF-7 breast cancer cells and
induces activation of latent TGF-β1 resulting in epithelial to
mesenchymal transition. Cell Commun Signal. 9:102011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li C, Li J, Wu D and Han G: The
involvement of survivin in insulin-like growth factor-1-induced
epithelial-mesenchymal transition in gastric cancer. Tumour Biol.
37:1091–1096. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sato A, Oya M, Ito K, Mizuno R, Horiguchi
Y, Umezawa K, Hayakawa M and Murai M: Survivin associates with cell
proliferation in renal cancer cells: Regulation of survivin
expression by insulin-like growth factor-1, interferon-gamma and a
novel NF-κB inhibitor. Int J Oncol. 28:841–846. 2006.PubMed/NCBI
|
